Engrail aims to build CNS pipeline by improving upon deprioritized assets

Nan Fung-backed Engrail to expand CNS pipeline starting with in-licensed GABA A modulator

With a $32 million series A round from Nan Fung, Engrail expects to advance its first CNS program into the clinic by 1Q21 as it builds out a pipeline of neuroscience drugs via deals for deprioritized assets.

Co-founded in 2019 by President and CEO

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE